Postoperative DAV-IFN-β therapy does not improve survival rates of stage II and stage III melanoma patients significantly

T. Matsumoto, K. Yokota, M. Sawada, A. Sakakibara, S. Shibata, S. Yasue, Y. Tomita, Hiroshi Yatsuya, M. Akiyama

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background DAV-interferon (IFN)-β therapy is a combination chemotherapy of dacarbazine (DTIC), nimustine (ACNU) and vincristine (VCR) with local subcutaneous injection of IFN-β that is widely employed as postoperative adjuvant chemotherapy to treat malignant melanoma in Japan. However, the efficacy of DAV-IFN-β therapy has not been confirmed by randomized controlled trials and the benefit of DAV-IFN-β therapy has not been established yet. This study evaluated the contribution of DAV-IFN-β therapy to improve survival of postoperative patients with cutaneous melanoma. Methods Patients with stage II or III cutaneous melanoma seen at Nagoya University Hospital from January 1998 to December 2009 were eligible for this study. Disease-free survival rates and melanoma-specific survival rates were evaluated. A propensity score was calculated to control for the effects of variables related to decisions regarding the application of DAV-IFN-β therapy. Results Eighty-two stage II and 60 stage III melanoma patients were included. In the post-matched stage II patients (17 matched pairs), the mean (±SE) disease-free survival rates were 39.9±13.7% for DAV-IFN-β therapy and 73.1±11.7% for non-use (hazard ratio for recurrence, 2.06; 95% CI, 0.63-6.69; P = 0.23), and the melanoma-specific survival rates were 66.2±20.0% for DAV-IFN-β therapy and 86.2±9.1% for non-use (hazard ratio for death, 1.09; 95% CI, 0.17-6.82; P = 0.93). In the post-matched stage III patients (nine matched pairs), the disease-free survival rates were 29.6±16.4% for DAV-IFN-β therapy and 33.3±15.7% for non-use (0.69; 95% CI, 0.22-2.17; P = 0.53), and the melanoma-specific survival rates were 55.6±16.6% for DAV-IFN-β therapy and 44.4±16.6% for non-use (0.67; 95% CI, 0.18-2.50; P = 0.55). Conclusions DAV-IFN-β therapy brought no significant improvement in either disease-free survival rates or melanoma-specific survival rates of patients with stage II or III cutaneous melanoma. A randomized controlled trial would be required to further evaluate the efficacy of DAV-IFN-β therapy as an adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)1514-1520
Number of pages7
JournalJournal of the European Academy of Dermatology and Venereology
Volume27
Issue number12
DOIs
Publication statusPublished - 01-12-2013

Fingerprint

Interferons
Melanoma
Survival Rate
Disease-Free Survival
Therapeutics
Nimustine
Dacarbazine
Adjuvant Chemotherapy
Skin
Randomized Controlled Trials
Propensity Score
Vincristine
Subcutaneous Injections
Combination Drug Therapy
Japan
Recurrence
Survival

All Science Journal Classification (ASJC) codes

  • Dermatology
  • Infectious Diseases

Cite this

Matsumoto, T. ; Yokota, K. ; Sawada, M. ; Sakakibara, A. ; Shibata, S. ; Yasue, S. ; Tomita, Y. ; Yatsuya, Hiroshi ; Akiyama, M. / Postoperative DAV-IFN-β therapy does not improve survival rates of stage II and stage III melanoma patients significantly. In: Journal of the European Academy of Dermatology and Venereology. 2013 ; Vol. 27, No. 12. pp. 1514-1520.
@article{c62dffca563944c5ab84dba5f6d61215,
title = "Postoperative DAV-IFN-β therapy does not improve survival rates of stage II and stage III melanoma patients significantly",
abstract = "Background DAV-interferon (IFN)-β therapy is a combination chemotherapy of dacarbazine (DTIC), nimustine (ACNU) and vincristine (VCR) with local subcutaneous injection of IFN-β that is widely employed as postoperative adjuvant chemotherapy to treat malignant melanoma in Japan. However, the efficacy of DAV-IFN-β therapy has not been confirmed by randomized controlled trials and the benefit of DAV-IFN-β therapy has not been established yet. This study evaluated the contribution of DAV-IFN-β therapy to improve survival of postoperative patients with cutaneous melanoma. Methods Patients with stage II or III cutaneous melanoma seen at Nagoya University Hospital from January 1998 to December 2009 were eligible for this study. Disease-free survival rates and melanoma-specific survival rates were evaluated. A propensity score was calculated to control for the effects of variables related to decisions regarding the application of DAV-IFN-β therapy. Results Eighty-two stage II and 60 stage III melanoma patients were included. In the post-matched stage II patients (17 matched pairs), the mean (±SE) disease-free survival rates were 39.9±13.7{\%} for DAV-IFN-β therapy and 73.1±11.7{\%} for non-use (hazard ratio for recurrence, 2.06; 95{\%} CI, 0.63-6.69; P = 0.23), and the melanoma-specific survival rates were 66.2±20.0{\%} for DAV-IFN-β therapy and 86.2±9.1{\%} for non-use (hazard ratio for death, 1.09; 95{\%} CI, 0.17-6.82; P = 0.93). In the post-matched stage III patients (nine matched pairs), the disease-free survival rates were 29.6±16.4{\%} for DAV-IFN-β therapy and 33.3±15.7{\%} for non-use (0.69; 95{\%} CI, 0.22-2.17; P = 0.53), and the melanoma-specific survival rates were 55.6±16.6{\%} for DAV-IFN-β therapy and 44.4±16.6{\%} for non-use (0.67; 95{\%} CI, 0.18-2.50; P = 0.55). Conclusions DAV-IFN-β therapy brought no significant improvement in either disease-free survival rates or melanoma-specific survival rates of patients with stage II or III cutaneous melanoma. A randomized controlled trial would be required to further evaluate the efficacy of DAV-IFN-β therapy as an adjuvant chemotherapy.",
author = "T. Matsumoto and K. Yokota and M. Sawada and A. Sakakibara and S. Shibata and S. Yasue and Y. Tomita and Hiroshi Yatsuya and M. Akiyama",
year = "2013",
month = "12",
day = "1",
doi = "10.1111/jdv.12040",
language = "English",
volume = "27",
pages = "1514--1520",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "12",

}

Postoperative DAV-IFN-β therapy does not improve survival rates of stage II and stage III melanoma patients significantly. / Matsumoto, T.; Yokota, K.; Sawada, M.; Sakakibara, A.; Shibata, S.; Yasue, S.; Tomita, Y.; Yatsuya, Hiroshi; Akiyama, M.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 27, No. 12, 01.12.2013, p. 1514-1520.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Postoperative DAV-IFN-β therapy does not improve survival rates of stage II and stage III melanoma patients significantly

AU - Matsumoto, T.

AU - Yokota, K.

AU - Sawada, M.

AU - Sakakibara, A.

AU - Shibata, S.

AU - Yasue, S.

AU - Tomita, Y.

AU - Yatsuya, Hiroshi

AU - Akiyama, M.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Background DAV-interferon (IFN)-β therapy is a combination chemotherapy of dacarbazine (DTIC), nimustine (ACNU) and vincristine (VCR) with local subcutaneous injection of IFN-β that is widely employed as postoperative adjuvant chemotherapy to treat malignant melanoma in Japan. However, the efficacy of DAV-IFN-β therapy has not been confirmed by randomized controlled trials and the benefit of DAV-IFN-β therapy has not been established yet. This study evaluated the contribution of DAV-IFN-β therapy to improve survival of postoperative patients with cutaneous melanoma. Methods Patients with stage II or III cutaneous melanoma seen at Nagoya University Hospital from January 1998 to December 2009 were eligible for this study. Disease-free survival rates and melanoma-specific survival rates were evaluated. A propensity score was calculated to control for the effects of variables related to decisions regarding the application of DAV-IFN-β therapy. Results Eighty-two stage II and 60 stage III melanoma patients were included. In the post-matched stage II patients (17 matched pairs), the mean (±SE) disease-free survival rates were 39.9±13.7% for DAV-IFN-β therapy and 73.1±11.7% for non-use (hazard ratio for recurrence, 2.06; 95% CI, 0.63-6.69; P = 0.23), and the melanoma-specific survival rates were 66.2±20.0% for DAV-IFN-β therapy and 86.2±9.1% for non-use (hazard ratio for death, 1.09; 95% CI, 0.17-6.82; P = 0.93). In the post-matched stage III patients (nine matched pairs), the disease-free survival rates were 29.6±16.4% for DAV-IFN-β therapy and 33.3±15.7% for non-use (0.69; 95% CI, 0.22-2.17; P = 0.53), and the melanoma-specific survival rates were 55.6±16.6% for DAV-IFN-β therapy and 44.4±16.6% for non-use (0.67; 95% CI, 0.18-2.50; P = 0.55). Conclusions DAV-IFN-β therapy brought no significant improvement in either disease-free survival rates or melanoma-specific survival rates of patients with stage II or III cutaneous melanoma. A randomized controlled trial would be required to further evaluate the efficacy of DAV-IFN-β therapy as an adjuvant chemotherapy.

AB - Background DAV-interferon (IFN)-β therapy is a combination chemotherapy of dacarbazine (DTIC), nimustine (ACNU) and vincristine (VCR) with local subcutaneous injection of IFN-β that is widely employed as postoperative adjuvant chemotherapy to treat malignant melanoma in Japan. However, the efficacy of DAV-IFN-β therapy has not been confirmed by randomized controlled trials and the benefit of DAV-IFN-β therapy has not been established yet. This study evaluated the contribution of DAV-IFN-β therapy to improve survival of postoperative patients with cutaneous melanoma. Methods Patients with stage II or III cutaneous melanoma seen at Nagoya University Hospital from January 1998 to December 2009 were eligible for this study. Disease-free survival rates and melanoma-specific survival rates were evaluated. A propensity score was calculated to control for the effects of variables related to decisions regarding the application of DAV-IFN-β therapy. Results Eighty-two stage II and 60 stage III melanoma patients were included. In the post-matched stage II patients (17 matched pairs), the mean (±SE) disease-free survival rates were 39.9±13.7% for DAV-IFN-β therapy and 73.1±11.7% for non-use (hazard ratio for recurrence, 2.06; 95% CI, 0.63-6.69; P = 0.23), and the melanoma-specific survival rates were 66.2±20.0% for DAV-IFN-β therapy and 86.2±9.1% for non-use (hazard ratio for death, 1.09; 95% CI, 0.17-6.82; P = 0.93). In the post-matched stage III patients (nine matched pairs), the disease-free survival rates were 29.6±16.4% for DAV-IFN-β therapy and 33.3±15.7% for non-use (0.69; 95% CI, 0.22-2.17; P = 0.53), and the melanoma-specific survival rates were 55.6±16.6% for DAV-IFN-β therapy and 44.4±16.6% for non-use (0.67; 95% CI, 0.18-2.50; P = 0.55). Conclusions DAV-IFN-β therapy brought no significant improvement in either disease-free survival rates or melanoma-specific survival rates of patients with stage II or III cutaneous melanoma. A randomized controlled trial would be required to further evaluate the efficacy of DAV-IFN-β therapy as an adjuvant chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84888204854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888204854&partnerID=8YFLogxK

U2 - 10.1111/jdv.12040

DO - 10.1111/jdv.12040

M3 - Article

VL - 27

SP - 1514

EP - 1520

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 12

ER -